

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2877)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO CESSATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Reference is made to the announcement of China Shineway Pharmaceutical Group Limited (the “**Company**”) dated 30 September 2022 in relation to, among other things, the cessation of Prof. Luo Guoan (“**Prof. Luo**”) as an independent non-executive director, and a member of the audit committee, nomination committee, and corporate social responsibility and sustainability committee of the Company with effect from 1 October 2022 (the “**Announcement**”). Unless otherwise specified, capitalized terms herein have the same meanings as those defined in the Announcement.

The Board would like to supplement that Prof. Luo will cease to be an independent non-executive Director in order to devote more time to pursue his personal interests.

Save as disclosed above, all other information of the Announcement remains unchanged.

By Order of the Board
China Shineway Pharmaceutical Group Limited
Li Zhenjiang
Chairman

Hong Kong, 30 September 2022

As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Xin Yunxia, Mr. Li Huimin and Mr. Chen Zhong; the non-executive Director is Mr. Zhou Wencheng and the independent non-executive Directors are Ms. Cheng Li, Prof. Luo Guoan and Mr. Liu Shun Fai.